Solera adds Noom to its employer and health plan weight management network
Solera Health added Noom to its employer and health-plan network on Sept. 1, 2026, meaning some members with GLP-1 prescriptions may now get free behavioral support alongside their medication through their existing benefits.

Solera Health, which builds curated digital-health networks for employers and health plans, added Noom to its weight-management lineup effective Sept. 1, 2026 [1][2]. The deal gives eligible members access to three Noom offerings: Noom Weight, a CDC Full Plus-recognized Diabetes Prevention Program (DPP), and a GLP-1 Companion program included at no extra cost [1][2]. Noom joins existing Solera network partners such as Betr, Transform, Weight Watchers and Modify Health [2].
Solera says its network spans more than 30 clinically validated digital health programs across eight chronic-condition categories, and it uses a matching algorithm to route members to the program that fits their needs rather than requiring separate vendor sign-ups [1]. Members reach Noom through Solera's existing benefit relationship, not through a direct Noom subscription.
The outcomes cited in the announcement come from Noom's own data and studies, not independent research [1]. Noom reports that 82% of Noom Weight members lost 5% or more of their body weight at one year, and that 64% of DPP participants prevented or delayed the onset of type 2 diabetes [1][2]. The company also reports a 0.28% average A1C reduction among DPP completers and $1,219 to $5,341 in average member health care savings over two years across the two programs [1].
The DPP's CDC Full Plus status is the highest recognition level the CDC gives diabetes prevention programs, reflecting stronger engagement, retention and outcomes data than lower recognition tiers, and it can help employers and health plans meet MSSP, ACA and other preventive-care compliance standards [1]. Noom's programs are built around cognitive behavioral therapy rather than meal plans or calorie counting, and the company says its methods are supported by more than 50 peer-reviewed publications, though the specific outcome figures above are Noom's own [1].
Why it matters for patients
For people already covered by a health plan or employer that uses Solera, this means Noom Weight, the DPP and the GLP-1 Companion program may now be reachable through an existing benefit rather than a separate paid subscription [1][2]. Solera and Noom both describe the GLP-1 Companion as behavioral and lifestyle support meant to run alongside a prescribed GLP-1 medication, not a replacement for it [2]. Access depends on whether a specific employer or health plan uses Solera's network and whether that plan includes Noom in its offerings; the sources do not say how many plans or how many people will actually be eligible [1][2].
Patients should also note that the headline statistics — the 82% weight-loss figure, the 64% diabetes-prevention rate, the A1C reduction and the savings estimates — are drawn from Noom's internal data rather than independent or peer-reviewed clinical trials [1]. That does not mean the numbers are wrong, but it does mean they were not produced or verified by an outside body, which is a different evidence standard than the CDC's Full Plus recognition applied to the DPP program specifically [1].
What happens next
The partnership took effect Sept. 1, 2026, and Noom's programs are now listed as available through Solera's network for eligible members [1][2]. The sources do not specify which health plans or employers have adopted the Noom offering, when broader rollout to specific plan members will happen, or whether additional outcome data will be published beyond Noom's own figures.
Images from the sources


Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.